Arcutis Announces Promotions on Executive Management Team

Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: GlobeNewswire
Strategic appointments support further growth and position Company for future success WESTLAKE VILLAGE, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced several promotions to support further growth of Arcutis and the ZORYVE® (roflumilast) portfolio. Patrick Burnett, MD, PhD, FAAD, chief medical officer, has been promoted to executive vice president, chief medical officer. Dr. Burnett joined Arcutis in August 2020 and has led the advancement of the Arcutis pipeline and scientific evidence generation. His accomplishments include the completion of numerous Phase
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual MeetingGlobeNewswire
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $13.00 to $15.00. They now have a "neutral" rating on the stock.MarketBeat
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.MarketBeat
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Mizuho from $20.00 to $21.00. They now have an "outperform" rating on the stock.MarketBeat
ARQT
Earnings
- 2/25/25 - Beat
ARQT
Sec Filings
- 2/25/25 - Form S-8
- 2/25/25 - Form 10-K
- 2/25/25 - Form 8-K
- ARQT's page on the SEC website